Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study
单位：[1]Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA[2]Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada[3]Department of Neuroendocrine and Gastrointestinal Oncology, Markey Cancer Center - University of Kentucky, Lexington, KY, USA[4]Oncology Business Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA[5]Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland[6]Department of Medical Oncology, University of Manchester, Institute of Cancer Studies, The Christie Hospital, Manchester, UK[7]Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KULeuven, Leuven, Belgium[8]Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan[9]Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
第一作者单位：[1]Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
推荐引用方式(GB/T 7714)：
J.C. Yao,S. Singh,E. Wolin,et al.Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study[J].ANNALS of ONCOLOGY.2016,27:
APA：
J.C. Yao,S. Singh,E. Wolin,M. Voi,L.B. Pacaud...&D.-Y. Oh.(2016).Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study.ANNALS of ONCOLOGY,27,
MLA：
J.C. Yao,et al."Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study".ANNALS of ONCOLOGY 27.(2016)
医学